Martin E. Blackstein

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet · 2006 · 2.6K citations

Gastrointestinal Oncology, Medicine, Pathology +5

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +6

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu et al. · The Lancet · 2009 · 1.3K citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +6

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

Irene L. Andrulis, Shelley B. Bull, Martin E. Blackstein et al. · Journal of Clinical Oncology · 1998 · 446 citations

Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

Christopher L. Corless, Karla V. Ballman, Cristina R. Antonescu et al. · Journal of Clinical Oncology · 2014 · 312 citations · Full text